intellectual

Intellectual Property

Since the business was founded, a key focus has been to establish strong patent protection around our key innovations.

We currently have three wholly owned patent families including 30 patents or patent applications. We are constantly expanding, broadening and developing our intellectual property portfolio.

We are also committed to protecting our intellectual property estate of patent rights and trade secrets and the potential commercial and clinical advantages this protection provides for our proprietary technology.

Our patent portfolio includes issued patents and patent applications in the world’s major markets, including the United States, Europe and Japan.

Protecting Recce’s unique and highly economical manufacturing process.

 Filed Expiry Status
Australia Australia 2028 Granted
United States of America(USA) USA 2029 Granted
European Union Europe 2028 Granted
Germany Germany 2028 Granted
Spain Spain 2028 Granted
France France 2029 Granted
United Kingdom(Great Britain) United Kingdom 2028 Granted
Italy Italy 2028 Granted
Sweden Sweden 2028 Granted
Japan Japan 2028 Granted
China China 2028 Granted

Protecting Recce’s drug delivery opportunities.

 Filed Expiry Status
Australia Australia 2035 Granted
United States of America(USA) USA 2035 Granted
European Union Europe 2035 Granted
Germany Germany 2035 Granted
Spain Spain 2035 Granted
France France 2035 Granted
United Kingdom(Great Britain) United Kingdom 2035 Granted
Italy Italy 2035 Granted
Sweden Sweden 2035 Granted
Japan Japan 2035 Pending
China China 2035 Pending

Protecting Recce’s anti-viral and anti-cancer applications.

Filed Expiry Status
   All PCT Countries  2034 Pending

Protecting RECCE® for use on antibiotic and pharmaceutical products and services

Filed Expiry Status
Australia  Australia 2026 Registered
United States of America(USA)  USA  2026 Registered
European Union  Europe  2026 Registered
Japan  Japan  2026 Registered
China China  2026 Registered

Sign up for news and updates

Receive news and information direct to your inbox.